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Strengths and limitations of this study
 ► The strengths of this study are the large sample 
size, long follow-up, large number of time intervals 
and presence of data of all outpatient prescriptions, 
including those initiated in secondary care. This 
makes it possible to focus on short-term and long-
term effects.
 ► Another strength is use of an interrupted time series 
design to evaluate the effect of this policy change. 
This analysis is the golden standard for evaluation of 
the effects of policy change.
 ► This study has several limitations. First, it is difficult 
to attribute the observed changes in benzodiazepine 
use to a single intervention, the reimbursement re-
striction policy, because many confounding factors 
change in time. However, to our knowledge there 
were no other health system changes that could be 
a rival explanation for the observed changes.
 ► Second, due to PHARMO regulations, only a 10% 
random sample of PHARMO database was obtained 
and analysed. Nevertheless, the statistical signifi-
cance of our analysis shows that the size of the data 
set is sufficient.
AbStrACt
Objectives Use of benzodiazepines has health risks. 
Reimbursement was restricted in the Netherlands from 
January 2009 onwards with the goal to reduce chronic 
use and healthcare expenditures. The aim of this study is 
to assess the initial and long-term effects of this policy on 
benzodiazepine use.
Design Interrupted time series analysis, segmented 
regression models, Kaplan-Meier survival analysis and Cox 
proportional hazards analysis.
Setting A 10% random sample of benzodiazepine 
dispensings by outpatient pharmacies between January 
2002 and August 2015 were obtained from the PHARMO 
database. This database covered a catchment area 
representing about 3.6 million residents in 2015.
Participants 2 500 800 benzodiazepine prescriptions from 
128 603 patients were included.
Intervention Reimbursement restriction policy from 
January 2009 onwards.
Outcome measures Changes in: the volume of dispensed 
prescriptions and doses, the incidence, prevalence of 
incidental, regular and chronic use and discontinuation 
rates of benzodiazepines.
results The volume of dispensed prescriptions and doses 
decreased by 12.5% (95% CI 9.0% to 15.9%) and 15.1% 
(95% CI 11.4% to 17.3%) respectively in January 2009 
compared with December 2008. A clear initial effect on 
the overall incidence (−14.7%; 95% CI −19.8% to 9.6%) 
and the prevalence of incidental (−17.8%; 95% CI −23.9% 
to 11.7%), regular (−20.0%; 95% CI −26.1% to 13.9%) 
and chronic (−16.0%; 95% CI −23.1% to 8.9%) use 
was observed. A statistically significant reduction in the 
monthly trend per 1000 medication users was observed 
for the overall incidence (−0.017; 95% CI −0.031 to 0.003) 
and the prevalence of incidental (−3.624; 95% CI −4.996 
to 2.252) but not for regular (−0.304; 95% CI −1.204 to 
0.596) and chronic (0.136; 95% CI −0.858 to 1.130) use. 
Patients who started treatment before policy had a slightly 
higher probability of discontinuation (HR=1.013; 95% CI 
1.004 to 1.022).
Conclusions The reimbursement policy had a significant 
initial effect on the volume, incidence and prevalence of 
benzodiazepine use. In addition, there is a statistically 
significant reduction in the monthly trend of overall 
incidence and of the prevalence of incidental use. No 
statistically significant reduction in the monthly trend 
of chronic use, the main purpose of the reimbursement 
restriction, could be demonstrated.
IntrODuCtIOn
Benzodiazepines (BZD) are widely used in 
the treatment of panic disorders, anxiety, 
insomnia and epilepsy. In addition to bene-
ficial therapeutic effects, chronic use of 
BZDs and BZD-related drugs can have 
health risks. It is associated with rebound 
insomnia, cognitive impairment and Alzhei-
mer’s disease,1 2 increased injurious falls3 
and (hip) fractures,4 5 traffic accidents6 and 
increased (overdose) mortality.7 8 In patients 
with substance abuse disorders it is associ-
ated with dependence, and risk of misuse 
and abuse.9 International clinical guidelines 
therefore state that the pros and cons need 
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to be carefully weighed when first prescribing a BZD to 
an individual patient and to restrict use to a short period. 
Despite increased awareness regarding risks associated 
with chronic use and recommendations to limit use in 
guidelines, these BZDs are among the most used medi-
cines in developed countries.10 Based on data of all health 
insurers the prevalence of BZD use in the Netherlands 
was 10.75% in 2007; 1 758 665 users filled 11 753 939 
prescriptions.11 Kurkoa et al estimated the prevalence of 
long-term use in the general population to be about 3%, 
based on a systematic review of register-based studies on 
BZD use published in 1993–2014.12 The relative propor-
tion of chronic use in adult BZD users ranges from 6% to 
76%.12 Chronic and excessive use became a public health 
issue and led to multiple campaigns to both reduce the 
prescription of these drugs and to stimulate discontinua-
tion of chronic treatment.13
Worldwide different strategies have been used to 
reduce the use of BZDs.13–17 One of these strategies is to 
influence behaviour of patients, physicians and/or phar-
macists by introduction of financial incentives, like pay 
for performance, copayments and restriction or termina-
tion of reimbursement.18 Since January 2009, BZDs are 
no longer reimbursed when used as anxiolytic, hypnotic 
or sedative in the Netherlands. The purpose of this policy 
change was to reduce chronic use and lower healthcare 
expenses. Coverage remained in case of epilepsy, pallia-
tive sedation and multiple psychiatric disorders, under 
the condition that the physician considered that no alter-
native treatment was suitable for the patient at hand. 
Before the introduction of this policy change, the Dutch 
Ministry of Healthcare calculated an annual net saving of 
€70 million for the years 2009–2013.19
Hoebert et al and Kollen et al studied the short-term 
effects of this reimbursement restriction in general prac-
tice. They showed that the policy change has led to a 
moderate decrease in BZD use in patients with newly diag-
nosed anxiety or sleeping disorder in general practice in 
2009,20 a decrease in the mean number of prescription 
days and a slight decrease in the number of long-term 
users in 2009 and 2010.21 However, the focus of their 
study was on newly diagnosed anxiety and sleeping disor-
ders, general practice and the short-term effect of the 
policy change.
This study is an analysis of the reimbursement restric-
tion in the Netherlands on the initial and long-term 
effects on the use of BZDs, in which the use is compared 
before and after the implementation of reimbursement 
restriction in January 2009.
MethODS
Setting
Data for this study were obtained from the PHARMO 
Outpatient Pharmacy Database ( www. pharmo. nl). This 
database comprises general practitioner (GP) and special-
ist-prescribed medication dispensed by the outpatient 
pharmacy. The dispensing records include information 
on type of product, date, strength, dosage regimen, quan-
tity, route of administration and prescriber specialty. 
Records are coded according to the WHO Anatomical 
Therapeutic Chemical (ATC) Classification System. 
Outpatient pharmacy data cover a catchment area repre-
senting about 3.6 million residents in 2015; almost a 
quarter of the Dutch population. Patient information 
includes gender, year of birth and socioeconomic status. 
Each patient is identified with an anonymous unique 
patient identification code that enables the observation 
of patient drug use in time.
In the Netherlands the coverage of pharmaceutical care 
is regulated by the Health Insurance Act.22 The Ministry 
of Health, Welfare and Sport and the Healthcare Insti-
tute of the Netherlands decide which drugs fall under the 
mandatory health insurance package. Registered medi-
cines have to be assessed before they can be included 
in the Medicines Reimbursement System (GVS). Medi-
cines listed in the GVS are fully or partially reimbursed 
by health insurers. Once a year the Ministry of Health, 
Welfare and Sport evaluates and actualises the list in 
order to keep healthcare affordable.
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient-rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
Study population
All medication records of a random 10% selection of 
all patients included in PHARMO who received at least 
one prescription for an oral BZD in the time period 
between January 2002 and August 2015 were collected 
and included. Due to the exceeding of the maximum 
allowed quantity of records by PHARMO a 10% sample 
was made available for this study. In the Netherlands, the 
following oral BZDs were available and dispensed during 
the study period: anxiolytics (N05BA: diazepam, chlor-
diazepoxide, oxazepam, clorazepate, lorazepam, broma-
zepam, clobazam, alprazolam), hypnotics and sedatives 
(N05CD: flurazepam, nitrazepam, flunitrazepam, lorme-
tazepam, temazepam, midazolam and N05CF: zopiclone, 
zolpidem) and antiepileptics (N03AE01: clonazepam).
Outcome measures
To estimate the effect of the policy change on the use of 
BZDs on population and patient level, the following four 
outcome measures were defined: dispensing volume, inci-
dence, intensity and discontinuation of BZD use.
Volume of dispensed BZDs: dispensed prescriptions and dispensed 
defined daily doses
First, to estimate the effect of the policy change on the 
total volume of BZD use, two outcome measures were 
chosen: the total number of dispensed prescriptions and 
the total amount of dispensed defined daily doses (DDD). 
The DDD is the assumed average maintenance dose per 
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Table 1 Possible effects of policy change in general
Effect type Level effect Delta slope (trend)
Initial and long-term 
effects
Decrease Negative
Initial effect only Decrease No change
Initial effect and long-
term opposite effects
Decrease Positive
Long-term effect only No change Negative
No effect No change No change
day for a drug used for its main indication in adults 
defined by the WHO. The purpose of the ATC/DDD 
system is to serve as a tool for drug utilisation monitoring 
and research in order to improve quality of drug use.
The total number of dispensed prescriptions and the 
total amount of dispensed DDDs per month were calcu-
lated. To correct for changes in the size of the dynamic 
population over time, 10% of the total number of medi-
cation users present in de PHARMO-database was calcu-
lated per month. This figure is then used as denominator 
to calculate the monthly dispensing rate and DDD rate per 
1000 medication users.
 
dispensing rate =
[number of dispensed presciptions
in 10% sample]
per month
10% ∗ [number of medication users present
in PHARMO database]
per month
∗ 1.000
 
 
DDD rate =
[sum of dispensed DDD
in 10% sample]
per month
10% ∗ [number of medication users present
in PHARMO database]
per month
∗ 1.000
 
Incidence of BZD use
Second, the incidence of BZD use was assessed. Incidence 
of use was defined as the absence of BZD use within 3 
months before a prescription was dispensed. The total 
number of medication users present per month in de 
PHARMO-database was used to calculate the incidence. 
The incidence therefore reflects the frequency of starting 
a BZD per month.
Intensity of prevalent BZD use: incidental, regular and chronic use
Third, the intensity of BZD use was assessed among 
prevalent users. Prevalent use was defined as the pres-
ence of at least one dispensed prescription in a calendar 
year. For each prevalent BZP user, the BZD use was clas-
sified as ‘incidental’, ‘regular’ and ‘chronic’ based on 
the number of days of use within 365 days after the first 
dispensed prescription in a calendar year; that is, 1–30 
days, 31–180 days and more than 180 days. The intensity 
of each prescription was calculated using the dispensed 
quantity and the dose regimen. In case of missing data, 
the duration of prescriptions was set on 30 days, which 
is the maximum dispensed quantity for BZDs in the 
Netherlands.
Discontinuation of BZD
Fourth, the treatment discontinuation of all prevalent 
BZD users was assessed. Discontinuation was defined as 
the absence of a BZD prescription within 91 days after the 
theoretical end date of the last BZD prescription. Kaplan-
Meier survival curves were constructed to visualise the 
difference in time to discontinuation between patients 
starting BZD use in the years 2004–2008 (before policy 
change) and 2009–2013 (after policy change).
Data analysis
The primary statistical model for the effect of the policy 
change on the dispensing rate, DDD rate, incidence and 
prevalence of BZD use was segmented regression, which 
is commonly used for estimating the effects of interven-
tions in interrupted time series (ITS) studies.23–25 The 
Cochrane Collaboration Guideline on ITS was used, 
applying a segmented regression model.26 Because the 
announcement of the policy change in September 2008 
could have influenced the number of filled prescrip-
tions due to anticipation, the data of the last 3 months 
before, and the first month after the intervention were 
excluded from the models. For methodological reasons, 
it is not possible to calculate the prevalence of initial, 
regular and chronic use for the years 2014 and 2015. A 
least squares regression line of predicted values is fitted 
in each segment, with the assumption of a linear trend 
over time. The goodness of fit of the models is provided 
with the R2 value.
In an ITS model, policy effects can be measured as a 
change in the slopes before and after policy, indicating 
the monthly trends, and the change in level after the 
implementation of the policy. Based on this analysis, 
table 1 gives a summary of possible effects from statistical 
analysis.
Cox proportional hazards analysis was applied to esti-
mate the strength of the association between the 5-year 
period before and after policy and the risk of discontinu-
ation, and was expressed as an HR with 95% CIs. Obser-
vations were censored at the 3 months before and at the 
1 month after the policy change. Age, sex and socioeco-
nomic status were considered potential confounders. 
Confounders resulting in a change of more than 10% in 
the risk estimate were included in the final model.
A sensitivity analysis was conducted to assess the 
influence of our definition of BZD discontinuation by 
expanding the 91-day period to 182 and 365 days and by 
defining incident as not having dispensed a BZD in the 
182 and 365 days before.
SAS Enterprise Guide V.7.1 (SAS Institute) and FoxPro 
V.6.0 (Microsoft, Redmond, Washington) were used for 
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data extraction and analysis. Statistical analyses were 
performed in SPSS V.24 (SPSS).
reSultS
Sample characteristics
A total of 2 500 800 filled prescriptions for oral BZD for 
128 603 unique patients were identified and included. 
Absolute sample characteristics per year are shown in 
table 2. Due to the dynamic character of the size of this 
database throughout the years the absolute number of 
patients and prescriptions fluctuates. The number of 
female BZD users is about twice as large as the number 
of male users. This ratio does not change substantially 
over time. The proportional use between the different 
age groups slowly shifts over time to an increase in the 
percentage of users over 65 years.
effect analysis
The effect of the policy on the volume; dispensing rate and on the 
dispensed DDD rate
Figure 1A shows the dispensing rate trend for BZDs, with a 
distinction between raw and estimated trends and upper 
and lower confidence limits (R2=0.75). At the beginning 
of the study the estimated dispensing rate was 114.4 (95% 
CI 102.9 to 125.8) per 1000 medication users per month. 
The estimated dispensing rate decreased by 12.5% (95% 
CI 9.0% to 15.9%) from 107.2 to 93.8 in January 2009 
just after the reimbursement restriction, which shows that 
the level of the filled prescription rate changed signifi-
cantly. In contrast, prepolicy trend (−0.085, p=0.002) 
was not significantly different from the postpolicy trend 
(−0.063, p=0.029); the monthly trend change after policy 
was 0.022 (95% CI −0.056 to 0.100) per 1000 medication 
users. Therefore, a long-term effect was lacking, so the 
policy had only an initial effect on the dispensing rate.
Figure 1B presents the monthly DDD rate, with a distinc-
tion between raw and estimated trends and upper and 
lower confidence limits (R2=0.92). At the beginning of 
the study the estimated DDD rate was 2274 (95% CI 2072 
to 2476) per month per 1000 medication users. The DDD 
rate decreased significantly by 15.1% (95% CI 11.4% to 
17.3%) from 1811 to 1538 in January 2009, just after the 
reimbursement restriction. The prepolicy trend (−5.85, 
p<0.001) was significantly different from the postpolicy 
trend (−2.82, p<0.001); the monthly trend change after 
policy was 3.033 (95% CI 1.592 to 4.474) per 1000 medi-
cation users. Therefore, the policy had, according to 
our definition, an initial effect and a long-term opposite 
effect on the DDD rate.
the effect of the policy on incidence of bZD use
Figure 2A shows the monthly incidence of BZD use, with a 
distinction between raw and estimated trends and upper 
and lower confidence limits (R2=0.77). At the beginning 
of the study the estimated incidence in April 2002 was 
12.9 (95% CI 11.1 to 14.7) patients per month per 1000 
medication users. The estimated incidence decreased 
significantly by 14.7% (95% CI 9.6% to 19.8%) or from 
12.0 to 10.24 per 1000 medication users in January 2009, 
just after the reimbursement restriction. The trend after 
policy (−0.028, p<0.001) was significantly different from 
the trend before policy change (−0.011, p=0.019); the 
monthly trend change after policy was −0.017 (95% CI 
−0.031 to 0.003) per 1000 medication users. Therefore, 
the policy change had an initial and long-term effect on 
the incidence of BZD use.
the effect of the policy on the intensity of bZD use: prevalence 
of incidental, regular and chronic use
Figure 2B shows the trend and level effect of the prev-
alence of incidental (R2=0.97), regular (R2=0.98) and 
chronic (R2=0.98) use, with a distinction between raw and 
estimated trends and upper and lower confidence limits. 
In 2002, the estimated prevalence per 1000 medication 
users was 78.1 (95% CI 73.7 to 82.5) for incidental, 59.9 
(95% CI 56.8 to 63.1) for regular and 60.2 (95% CI 57.4 
to 63.1) for chronic use. Before policy there was an esti-
mated annual reduction of −0.700 (p=0.018) for regular 
and −1.052 (p=0004) for long-term use. The estimated 
prepolicy trend shows an increase in the prevalence of 
incidental use from 2002 to 2008 (0.888, p=0.039). The 
absolute-level effects for incidental use are −15.0 (95% CI 
−20.2 to 9.9), for regular use −11.1 (95% CI −14.5 to 7.7) 
and for chronic use −8.4 (95% CI −12.1 to 4.7) per 1000 
medication users. The relative-level effects are shown in 
table 3. The postpolicy trend for incidental use (−2.736, 
p=0.002) was significantly different from the trend before 
policy (0.888, p=0.039); the yearly trend change after 
policy was −3.624 (95% CI −4.996 to 2.252) per 1000 
medication users. Therefore, the policy had an initial 
and long-term effect on the prevalence of incidental 
use. The postpolicy trends for regular (−1.003, p=0.034) 
and chronic (−0.915, p=0.069) use were not significantly 
different from the prepolicy trends; the trend changes 
after policy were −0.304 (95% CI −1.204 to 0.596) for 
regular and 0.136 (95% CI −0.858 to 1.130) for chronic 
use. Therefore, the policy change had only an initial 
effect on the prevalence of regular and chronic use.
Table 3 summarises the effects of the policy on the 
volume (dispensing rate and dispensed DDD rate), the 
incidence and the intensity (prevalence of incidental, 
regular and chronic use) of BZD use, as previously 
described.
the effect of the reimbursement restriction on the 
discontinuation of bZD treatment
The Kaplan-Meier curves for the 5-year period before and 
after policy change, illustrating the time to discontinua-
tion after the start date of the first filled BZD prescription, 
showed no visual difference (see online supplementary 
figure 1).
Cox proportional hazards analysis was used to compare 
the risk of discontinuation between patients starting BZDs 
before (2004–2008) and after (2009–2013) the reim-
bursement restriction. A small but significant difference 
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Figure 1 The volume of benzodiazepine (BZD) use over time. (A) The dispensing rate, the total dispensed prescriptions 
per month per 1000 medication users. (B) The defined daily dose (DDD) rate, the total DDDs dispensed per month per 1000 
medication users.
in discontinuation rate was observed (HR=1.013; 95% CI 
1.004 to 1.022), indicating that patients who started 
treatment had a higher chance of discontinuation in the 
5-year period after the policy change. Adjusting for age, 
sex and socioeconomic status as potential confounders 
did not result in a change of more than 10% of the HR, 
so they were not included in the final model.
DISCuSSIOn
This study is the first study which evaluates the initial 
as well as the long-term effects of the reimbursement 
restriction policy on BZD use in the Netherlands. Just 
after the policy change the total number of dispensed 
prescriptions as well as dispensed DDD dropped signifi-
cantly. This effect persisted in the years after the policy 
change. On the patient level the reimbursement policy 
had a significant initial effect on the prevalence of both 
incidental, regular and chronic use. This effect was most 
prominent in regular use. Only in case of incidental use, 
there was a stronger monthly decrease in the number 
of users after the reimbursement restriction policy, indi-
cating a long-term effect. A long-term effect on chronic 
use is lacking. The policy change had a significant initial 
effect on the overall incidence of BZD use. The monthly 
decrease in incidence is greater after policy, which is a 
strong indication for a long-term effect. When we compare 
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Figure 2 Incidence and intensity of benzodiazepine (BZD) use over time. (A) Incidence per month per 1000 medication users. 
(B) Prevalence of incidental, regular and chronic use of BZD per calendar year per 1000 medication users.
discontinuation of treatment in the 5-year period before 
and after the restriction policy the reimbursement had a 
statistical significant effect (HR 1013). This effect is small 
and does not appear to be of clinical significance.
Absence of a long-term effect on chronic use could be 
caused by the proportion of patients with the indication of 
epilepsy and multiple psychiatric disorders, where reim-
bursement is maintained. Moreover, BZD dependency 
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Table 3 Summary of effects of reimbursement restriction of BZDs on the volume, incidence and prevalence of 
benzodiazepine use
Effects of policy change
Relative-level effect
(95% CI)
Delta slope (trend)
(95% CI)
Dispensing rate Initial effect only −12.5% (−15.9% to 9.0%) 0.022 (−0.056 to 0.100)
Dispensed DDD rate Initial effect and long-term 
opposite effect
−15.1% (−17.3% to 11.4%) 3.033 (1.592 to 4.474)
Incidence Initial and long-term effects −14.7% (−19.8% to 9.6%) −0.017 (−0.031 to 0.003)
Prevalence incidental use Initial and long-term effects −17.8% (−23.9% to 11.7%) −3.624 (−4.996 to 2.252)
Prevalence regular use Initial effect only −20.0% (−26.1% to 13.9%) −0.304 (−1.204 to 0.596)
Prevalence chronic use Initial effect only −16.0% (−23.0% to 8.9%) 0.136 (−0.858 to 1.130)
BZD, benzodiazepine; DDD, defined daily dose.
plays a bigger role in this subgroup, which might have an 
impact on discontinuation rates. Unfortunately, we have 
no data about indications and reimbursement on the 
individual patient level. Another mechanism we observe 
in daily practice can also play a part; prescribers can 
declare that a patient has multiple psychiatric disorders, 
although it is not true, only to keep the drug reimbursed. 
This could occur more frequently in chronic use of BZDs.
Another possible explanation for this phenomenon 
could be the difference in financial threshold in case of 
incidental use. The price of BZDs is relatively low, about 
€0.5–€2 for a month, compared with the pharmacist’s 
service fee for dispensing (€6). The pharmacist’s fee for 
dispensing a first prescription (€12) is about twice as 
high as for a subsequent prescription, which means that 
the financial threshold to start exceeds the threshold to 
continue BZD use. This could be an explanation for the 
fact that the long-term impact on the incidence and the 
prevalence of incidental use is positive and lacking in case 
of both regular and chronic use. Another argument is 
that it might be more difficult for physicians to stop treat-
ment of individual patients than to prevent initiation, 
especially when it comes to addictive medication. Medi-
cation prescribing is a complex process where behaviour 
and dynamics regarding initiation are often less compli-
cated than in case of medication cessation.
In addition to reduce chronic use, another aim of the 
reimbursement restriction was to reduce drug expendi-
tures. Unfortunately, in the PHARMO Outpatient Phar-
macy Database, data on costs and coverage status of the 
dispensed BZD were missing. In 2009, the year after the 
policy change, about 32% of dispensed prescriptions were 
covered by health insurance and €79 million was spent on 
BZDs, of which €56 million was paid by the users them-
selves.27 While health insurers paid only 32% of all BZDs 
in 2009, in 2017 that share grew to almost half.28 The 
absolute number of reimbursed prescriptions increased 
annually from 3350 million in 2009 to 5033 million in 
2017. As a result, the annual net saving of €70 million 
for the years 2009–2013, calculated by the Dutch Ministry 
of Healthcare in 2008, has not been achieved. This is a 
simple way of estimating the intended financial effects 
on an annual basis. Only an in-depth (health-economic) 
analysis of health gain and loss, healthcare utilisation and 
substitution to other (pharmaco)therapies, like antide-
pressants or psychotherapy, can reveal the true budget 
and health impact of the reimbursement restriction 
policy. The International Task Force on Benzodiazepines 
suggests that warnings against the negative effects of BZD 
might be influenced by the pharmaceutical industries in 
order to promote the use of newer patented alternatives 
like the serotonin reuptake inhibitors for anxiety.29 These 
approaches are beyond the scope of this article.
The strengths of this study are the large sample size, the 
long follow-up, the large amount of time frames and the 
presence of data of all outpatient prescriptions, including 
those initiated in secondary care. This makes it possible 
to focus on short-term and long-term effects. Another 
strength is use of an ITS design to evaluate the effect of 
this policy change. This analysis is the golden standard for 
evaluation of the effects of policy change.
This study has several limitations. First, it is difficult 
to attribute the observed changes in BZD use to a single 
intervention, the reimbursement restriction policy, 
because many confounding factors change in time. 
However, to our knowledge there were no other health 
system changes that could be a rival explanation for the 
observed changes. Second, due to PHARMO regulations, 
only a 10% random sample of PHARMO database was 
obtained and analysed. Nevertheless, the statistical signif-
icance of our analysis shows that the size of the data set 
is sufficient. Finally, in this study dispensed prescriptions 
were used as an approximation of BZD use. This may not 
always be accurate as in fact not all dispensed prescrip-
tions have led to their consumption.
Not only Dutch policymakers have chosen to apply 
financial incentives to reduce BZD use. In Italy, exclusion 
from reimbursement in 1994 was not enough to reduce 
the use of BZDs. Despite the reimbursement policy the 
total BZDs sold from 1989 to 1999 showed a 53% increase 
in Italy.30 Although a French pay-for-performance strategy 
had a modest effect on the achievement of GPs regarding 
BZD indicators,16 it did not lead to the intended decrease 
of the use of BZDs in 2012.31 In a US policy, exclusion 
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from the Medicare Part D formulary in 2006 led to an 
immediate and sustained drop of 5% in number of BZD 
prescriptions filled by seniors.32
Compared with these policies the effect of the Dutch 
reimbursement restriction policy is high. In contrast, 
compared with the effect of the New York State Regu-
latory action in 1989 that required triplicate forms for 
BZD prescribing which created a higher bureaucratic 
threshold for BZD prescribing which resulted in a 60% 
reduction in BZD use,33 the effect of the reimbursement 
restriction in the Netherlands is modest.
A decrease in the use of BZDs does not automatically 
lead to a reduction of the negative events with which they 
are associated in the literature. For example, Wagner et al 
showed that this policy, despite this substantial reduction 
in the use of BZDs, did not lead to a decrease in hip frac-
tures.15 So, substantial reductions in the use of BZD do 
not necessary lead to expected clinical benefits.
Not only in case of BZDs are introducing financial 
incentives used to influence the use of prescription drugs. 
Green et al reviewed the effects of reimbursement restric-
tions on the use of several drug classes.34 Due to substan-
tial differences in objectives, context and the presence 
of alternatives, it is difficult to generalise the results and 
to compare with the outcomes of this study. Green et al 
stated that policy design needs to be based on research 
quantifying the harm and benefit profiles of target and 
alternative drugs to avoid unwanted health system and 
health effects.
When policy changes are so profound and affect so 
many people, it is the responsibility of the authorities to 
make a sound assessment and share it with society. This 
information provides essential insights into ‘what to do’ 
and ‘what not to do’ in drug reimbursement policy. This 
allows policymakers to learn from previous initiatives and 
from initiatives abroad, and enables them to deploy reim-
bursement policy in an evidence-based manner. However, 
success of reimbursement policy is difficult to predict 
and highly dependent on purpose and context and a 
result of the complex interaction between social, cultural, 
economic and systemic factors. Neglecting this complex 
dynamic can cause failure of copied successful policies.
Despite these limitations, this study provides us 
important insights into the effects of the policy on the 
use of BZDs in the Netherlands and gives direction for 
follow-up research. Does this policy lead to intended or 
unintended substitution; the shift to other medicines or 
therapies or substance abuse? And, are there differences 
between prescribers, different BZDs, age groups and 
socioeconomic status? It is also important to investigate 
whether the decrease in the use of BZDs actually leads to 
a reduction of the associated adverse events like addic-
tion, fall incidents, hip fractures and the impact on sick-
ness absence and social costs in the Netherlands.
This is the first study with an ITS design on the initial 
and long-term effects of the 2009 reimbursement restric-
tion policy on BZD use in the Netherlands. The policy 
change has a significant initial effect on the volume and 
incidence of BZD use. In addition to an initial effect, 
there is a long-term effect in case of incidental use and 
overall incidence. Although there is a significant initial 
effect, the long-term effect on the chronic use of BZD, 
the main purpose of the reimbursement restriction, is 
lacking.
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